Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | SHP099 | -inf | 0.8081 | ||||||
| HCC1500 | Rucaparib | #NAME? | 1.0742 | 0.0000 | 0.1000 | 0.0100 | |||
| HCC1500 | Senexin B | -inf | -0.9794 | ||||||
| MDA-MB-157 | MK 1775 | -inf | -0.8758 | ||||||
| HCC1954 | BMS-265246 | -inf | -0.1012 | ||||||
| HCC70 | THZ1 | -inf | -0.8868 | ||||||
| HCC1500 | SHP099 | -inf | -0.1868 | ||||||
| HCC1500 | THZ1 | -inf | -0.9999 | ||||||
| HCC1419 | LY3023414 | -inf | -0.6005 | ||||||
| HCC1419 | AZD6738 | -inf | 0.3243 | ||||||
| HCC1500 | THZ531 | -inf | -0.9990 | ||||||
| MDA-MB-157 | Ulixertinib | -inf | 0.3233 | ||||||
| MDA-MB-134-VI | RO-3306 | -inf | 0.0360 | ||||||
| MCF 10A | Alvocidib | -inf | -0.7589 | ||||||
| HCC1806 | THZ1 | -inf | -0.5805 | ||||||
| HCC1395 | AZD6738 | -inf | -0.3125 | ||||||
| MDA-MB-134-VI | GSK2334470 | -inf | 0.1440 | ||||||
| Hs 578T | BMS-265246 | -inf | |||||||
| MDA-MB-134-VI | Alvocidib | -inf | -0.4621 | ||||||
| MDA-MB-134-VI | Ulixertinib | -inf | -0.2948 | ||||||
| T47D | Ribociclib | -inf | 0.0709 | ||||||
| HCC1806 | BMS-265246 | -inf | -0.0075 | ||||||
| MDA-MB-134-VI | BMS-265246 | -inf | 0.0268 | ||||||
| MDA-MB-134-VI | AZD6738 | -inf | 0.1117 | ||||||
| HME1 | THZ1 | -inf | -0.3007 |